Curia´s Patented Process for Intermediates Useful for Upadacitinib
white paper
internal
In this white paper, we describe how Curia’s patented new process can obtain intermediates in the synthesis of compounds such as Upadacitinib without the need of highly toxic reagents. If you want to learn more, check the asset below or Curia’s patent application WO2021/123288.